Retroviral vectors derived from murine leukemia virus (MLV) have been pseudotyped with a variant of the envelope glycoprotein (Env) of nonpathogenic simian immunodeficiency virus from African green monkeys (SIVagm) to result in [MLV(SIVagm-wt)] vector particles. The variant env gene encodes a full-length surface envelope glycoprotein (SU) and a C-terminally truncated transmembrane protein (TM). To change the coreceptor usage of this vector from CCR5 to CXCR4, which is predominant on human CD4-positive lymphocytes, the putative V3-loop of SIVagm SU was replaced by that of the T cell tropic HIV-1 variant BH10. The resulting [MLV(SIVagm-X4)] vectors were shown to specifically transduce CD4/CXCR4positive cell lines, demonstrating the equivalent function in cell entry and choice of coreceptor usage of the V3-loops of SIVagm and HIV-1. These modified vectors were able to transduce primary human lymphocytes and were resistant to neutralization by sera from HIV-1-infected individuals. The [MLV(SIVagm-X4)] pseudotype vector generated is thus a promising candidate vector, e.g., for in vivo gene therapy of HIV-1 infection. © 2002 Elsevier Science (USA) 
INTRODUCTION
CD4 ϩ T cells are promising targets for gene transfer approaches aiming at the prevention of human immunodeficiency virus (HIV) infection or the treatment of AIDS. To develop CD4-specific retroviral vectors, Moloney murine leukemia virus (MLV) has been pseudotyped with variant envelope glycoprotein (Env) of a variety of lentiviruses including HIV-1 (Schnierle et al., 1997; Mammano et al., 1997; Lodge et al., 1998) , HIV-2 (Höhne et al., 1999) , the simian immunodeficiency virus from African green monkeys (SIVagm) (Stitz et al., 2000) , and SIVmac from rhesus macaques (Indraccolo et al., 1998) . Truncation of the C-terminal domain of the transmembrane envelope glycoprotein (TM) of HIV-1, HIV-2, and SIVagm was necessary to allow formation of infectious pseudotype vector particles. In contrast to [MLV(HIV-1)] vectors, [MLV-(SIVagm) ] vectors were shown to be resistant to neutralization by a variety of sera from HIV-1 seropositives (Stitz et al., 2000) . Therefore, [MLV(SIVagm)] vectors may be superior to [MLV(HIV-1)] vectors for in vivo gene therapy of HIV-1-infected patients.
Infection of cells by HIV and SIV requires a functional interaction of the surface envelope glycoprotein (SU) with at least two cell-surface molecules. These are the primary receptor CD4 and a coreceptor. All coreceptors identified until today belong to the chemokine receptor family of seven-membrane spanning receptors Deng et al., 1996) . The major HIV-1 coreceptors are CCR5 and CXCR4, while most SIV isolates use CCR5 or alternative coreceptors such as Bob or Bonzo (Deng et al., 1997) . However, depending on the donor, 50-80% of human CD4-positive T cells are CXCR4-positive, whereas only 5-15% express CCR5 (Ostrowski et al., 1998; Vassiliadou et al., 1999; Blanco et al., 1999; I. Schmitt and K. Cichutek, unpublished data) . The pattern and regulation of Bonzo expression on the surface of CD4-positive cells closely parallel that of CCR5 and are inversely correlated with CXCR4 expression (Unutmaz et al., 2000) . Thus, we attempted to generate [MLV(SIVagm)] vector particles able to use the coreceptor CXCR4 for cell entry and would therefore be suitable for efficient transduction of the majority of the target T cells of HIV-1 replication, i.e., human CD4/CXCR4-positive T cells.
The cell tropism of HIV-1 is mainly determined by the V3-loop region of SU (Hwang et al., 1991; Shioda et al., 1992; Choe et al., 1996; Speck et al., 1997) . Exchange of the V3-loops between CCR5-tropic and CXCR4-tropic HIV-1 strains were shown to be sufficient for a switch of the cell tropism of the resulting viruses (Sato et al., 1999; LaBranche et al., 1999) . Analysis of HIV-1 Env chimeras containing the V3-loop of an SIVmac/HIV-1 hybrid virus indicated that the V3-loop is the major determinant of CXCR4 specificity, whereas the V1and V2-loops of Env are more important for binding to coreceptors other than CXCR4. It is well known that basic amino acid residues in the V3-loop of HIV-1 allow efficient utilization of CXCR4 (Shioda et al., 1992) . However, similar changes in the V3-loop of SIVmac SU did not enable the use of CXCR4 (Meister et al., 2001) , and also substitution of the complete V3-loop of the SIVmac SU against that of HIV-1 did not allow the generation of replication-competent SIVmac variants with alternative coreceptor usage (Kirchhoff et al., 1994a; Mamounas et al., 1995) .
Although the V3-loop of SIVagm has not been sufficiently analyzed, we speculated that it would play a similar role in coreceptor binding as that of HIV-1. To switch the coreceptor usage of [MLV(SIVagm-wt)] vectors containing the truncated SIVagm Env variant encompassing the wild-type SU from CCR5 to CXCR4, we identified a putative V3-loop region in the SIVagm SU. This region was replaced by the V3-loop of the T cell tropic HIV-1 variant BH10. We show here that the resulting [MLV (SIVagm-X4)] pseudotype vector particles were able to transduce CD4/CXCR4-positive cells, whereas cell entry was no more mediated by CCR5 or Bonzo. This demonstrates the functional equivalency of the V3-loop of SIVagm with that of HIV-1 in terms of cell entry and coreceptor recognition. [MLV(SIVagm-X4)] vectors were able to transduce primary human lymphocytes and were still resistant to neutralization by sera from HIV-1-seropositives, thus providing an important advantage over [MLV(HIV-1)] vectors for future in vivo gene therapy applications.
RESULTS

Substitution of the SIVagm V3-loop in the surface envelope glycoprotein
By comparing the env gene sequence of a molecular clone of SIVagm3 (SIVagm3mc) with that of the CD4/CXCR4-tropic HIV-1 strain BH10 (Wong-Staal et al., 1985) and the CD4/CCR5-tropic HIV-1 strain MBK (Cichutek et al., 1992) , a 34 amino acid stretch in the SU of SIVagm3mc was identified as the HIV-1 V3-loop homolog due to the presence of cystein residues at the 5Ј and 3Ј ends as well as other identical amino acids in similar positions ( Fig. 1B ). Within this region, the amino acid sequence homology between HIV-1 BH10 and SIVagm3mc was 33%.
To switch the coreceptor usage of SIVagm, the V3-loop encoding region was substituted by that of the CD4/CXCR4tropic HIV-1 variant BH10. Using fusion PCR, the V3-loopencoding region of plasmid pRep⌬10env, which encodes a C-terminally truncated env gene and the entire rev gene of SIVagm ( Fig. 1A) , was replaced by the V3-loop of the T cell tropic HIV-1 variant BH10 (Fig. 2) . The overall structure of the resulting chimeric env expression construct designated Rep⌬10env-X4 was verified by sequence analysis (data not shown).
To prove functional expression of the V3-loop-modified SIVagm Env in human 293T cells, fusion activity was investigated. For this purpose, 293T cells were transfected with plasmid pRep⌬10env or pRep⌬10env-X4, respectively, and cocultivated with the CD4-positive human T cell line Molt4/8. Molt4/8 cells express high levels of CXCR4 and only a low level of CCR5 (Dejucq et al., 1999) . After 2 days, large syncytia were detected by light microscopy in cocultures of 293T cells expressing SIVagm-wt Env or SIVagm-X4 Env, but not in untransfected cultures used as controls ( Fig. 3 ). Following in situ immunoperoxidase assay (IPA) using serum from an SIVagm3-positive macaque, the syncytia were stained, indicating that their formation was indeed induced by expression of the respective fusion-competent env gene products (Fig. 3 ). These data indicated (i) expression of env gene products on the cell surface, (ii) binding of env gene products to receptors on the surface of Molt4/8 cells, and (iii) fusion capacity of both variant envelope glycoproteins. Obviously, due to the known high sensitivity of this syncytium assay, the low levels of CCR5 on Molt4/8 cells were sufficient for syncytium induction by encoding also rev sequences as well as a hygromycin B expression cassette (not shown). The C-tail of the transmembrane protein (TM) was truncated to enable pseudotyping of MoMLV capsids. pRep⌬10env encodes the full-length wild-type SIVagm3mc SU Stitz et al., 2000) . TMR: transmembrane region. (B) Comparison of the V3-loop amino acid sequences of SIVagm3mc, T cell-tropic HIV-1 strain BH10 (Wong-Staal et al., 1985) , and macrophage-tropic HIV-1 strain MBK (Cichutek et al., 1992) .
the SIVagm-wt Env. It was concluded that SIVagm-X4 Env was fully functional.
Transient generation of infectious [MLV(SIVagm-X4)] pseudotype vector particles and construction of stable packaging cell lines
To generate retroviral pseudotype vector particles, triple cotransfections of 293T cells were performed using the packaging signal psi-negative MoMLV gag/pol encoding plasmid pHIT60, the psi-positive MLV-derived ret-roviral transfer vector MFG-nlsLacZ containing the lacZ marker gene, and either plasmid pRep⌬10env or pRep⌬10env-X4, the latter two encoding the psi-negative SIVagm Env variants ( Fig. 1A) . Two days after transfection, supernatants were filtered and used for the transduction of GHOST cell lines (Cecilia et al., 1998) , which express either human CD4 alone (GHOST-parental) or CD4 in conjunction with one of the HIV-1 coreceptors CCR5, CXCR4, or Bonzo. Two days posttransduction the cells were stained to detect transduced, ␤-galactosi- dase-expressing cells. Using [MLV(SIVagm-wt)] vectors, efficient transduction was obtained in GHOST-CCR5 cells [corresponding to 1.3 ϫ 10 4 infectious units per ml (i.u./ml)] and in GHOST-Bonzo cells (5.8 ϫ 10 3 i.u./ml).
[MLV(SIVagm-X4)] vectors were able to transduce GHOST-CXCR4 cells (3.9 ϫ 10 3 i.u./ml). All other GHOST cells including GHOST-parental cells revealed only lowlevel transduction which was most likely due to a low level of endogenous expression of CXCR4 and Bonzo (Edinger et al., 1998) . This demonstrated that the tropism of the [MLV(SIVagm-X4)] vector was changed from CD4/ CCR5 and CD4/Bonzo to CD4/CXCR4 by the V3-loop exchange.
For continuous production of supernatants containing high titers of [MLV(SIVagm-wt)] and [MLV(SIVagm-X4)] pseudotype vectors, stable packaging cell lines were generated. Therefore, TELCeB6 cells (Cosset et al., 1995) , which contain a psi-positive retroviral transfer vector and a psi-negative MLV gag/pol expression plasmid, were transfected either with plasmid pRep⌬10env or with pRep⌬10env-X4, both encoding a hygromycin B resistance gene in addition to the SIVagm Env variant. After hygromycin B selection of the transfected cells and screening of more than 200 resistant colonies per cell line for vector production, we obtained cell clone wt.6 producing [MLV(SIVagm-wt)] vector particles with a titer of 7.6 ϫ 10 5 i.u./ml as determined in GHOST-CCR5 cells, and cell clone X4.3 producing 6.0 ϫ 10 3 i.u./ml of [MLV-(SIVagm-X4)] vector particles as determined in GHOST-CXCR4 cells. Using ultracentrifugation, 100-fold concentration of the vector stocks was routinely achieved.
Detection of truncated SIVagm Env in supernatant of packaging cells
To analyze the expression of the SIVagm Env variants, 20 ml culture supernatant from the stable packaging cells were pelleted by ultracentrifugation through sucrose cushions. Vector particles obtained in the pellets were analyzed by Western blotting (Fig. 4 ). Purified pellet from supernatants of nontransfected TELCeB6 cells was used as a negative control. Following staining of Western blots using serum from an SIVagm3-infected macaque, a characteristic band corresponding to gp140-SU of SIVagm was detected in supernatants obtained from [MLV(SIVagm-wt)] and [MLV(SIVagm-X4)] vector-producing cells, but not in the negative control pellet. However, the amount of gp140-SU detected in supernatants of [MLV(SIVagm-X4)]-producing cells was significantly lower than that detected in supernatants of [MLV(SIVagm-wt)]-producing cells. A band corresponding to a molecular weight of about 29 kDa was detected in comparable amounts in both vector pellets, but not in the negative control. The apparent molecular weight of 29 kDa corresponded to the theoretical molecular weight of the truncated SIVagm TM protein considering the truncation of the wild-type gp45-TM by 135 C-terminal amino acids. Since the levels of the gp29-TM⌬10 proteins detected in supernatants from [MLV(SIVagm-wt)]and [MLV(SIVagm-X4)]-producing cells were equivalent, the difference in the amounts of gp140-SU is most probably due to increased shedding of the gp140-SU from [MLV(SIVagm-X4)]-producing cells or respective vectors. Although incorporation of the Env proteins into the respective vector particles can be assumed, it is not unequivocally proven by the Western blot data, since supernatants from TE671 cells, transfected either with plasmid pRep⌬10env or with pRep⌬10env-X4 and thus expressing only Env proteins but no other vector components, revealed a similar Env protein pattern (data not shown), thus indicating copelleting of nonincorporated Env. Additional bands were obviously unspecific because they were also detected in the negative control pellet. To detect MLV proteins, the blot was intensively washed and relabeled using a polyclonal serum able to detect p30-Gag of MLV. Bands of the corresponding molecular weight were stained in the supernatants from SIVagm env-transfected and mock-transfected TELCeB6 cells ( Fig. 4) , providing evidence for the release of vector particles containing MLV capsids.
Coreceptor usage of [MLV(SIVagm-X4)] vectors
To investigate the usage of additional coreceptors besides CCR5, Bonzo, and CXCR4 by the [MLV(SIVagm)] vectors generated, we transduced a panel of 10 GHOST cell lines, each expressing either human CD4 alone or CD4 in conjunction with one of several chemokine receptors known to function as coreceptors for cell entry of HIV and SIV. Cultures of all GHOST cell lines were incubated with various dilutions of [MLV(SIVagm-wt)] or [MLV(SIVagm-X4)] vector-containing supernatants harvested from the stable packaging cell lines. As controls, [MLV(HIV-1)] vectors which were generated either from packaging cell line K52SR20 harboring the CXCR4-tropic env of HIV-1 BH10 (Stitz et al., 1998) or from packaging cell line MBK15 harboring the CCR5-tropic env gene of HIV-1 BH10 modified by inserting the V3-loop of MBK (I. Schmitt and K. Cichutek, unpublished data) were used. These vectors, here designated as [MLV(HIV-X4)] and [MLV(HIV-R5)], respectively, were generated with titers of 7.0 ϫ 10 5 and 1.0 ϫ 10 6 i.u./ml, respectively, tested on GHOST-CXCR4 or GHOST-CCR5 cells. Two days after transduction, the percentage of transduced cells was determined by X-Gal staining (Fig. 5 ).
Using [MLV(SIVagm-wt)] vectors, cells expressing CD4 and CCR5 were transduced most efficiently (Fig. 5A ). GHOST cells expressing CD4 and Bonzo were also transduced, albeit at a lower percentage of about 60% relative to the CD4/CCR5 cells. A background transduction below 3% was observed with the other GHOST cell lines and was hypothesized to be due to low endogenous expression of Bonzo in GHOST cells (Edinger et al., 1998) . [MLV(HIV-R5)] vectors used CCR5 as a coreceptor but were not able to use any further coreceptor.
[MLV(SIVagm-X4)] vector particles revealed an essentially identical transduction pattern as [MLV(HIV-X4)] vectors encompassing the same V3-loop derived from HIV-1 BH10 Env (Fig. 5B ). Aside from efficient transduction of GHOST-CXCR4 cells, a pattern of background transduction of other GHOST cells mediated by endogenous CXCR4 expression (Edinger et al., 1998) was also iden-tical for [MLV(SIVagm-X4)] and [MLV(HIV-X4)] vectors. Thus, the coreceptor switch from CCR5/Bonzo to CXCR4 due to exchange of the V3-loop observed when using transiently generated [MLV(SIVagm)] vectors was confirmed with supernatant from stable cell lines.
To further prove the exclusive usage of the CXCR4 coreceptor by [MLV(SIVagm-X4)] vector, inhibition experiments were carried out using the stromal-derived factor 1 (SDF-1), the natural ligand of CXCR4 (Oberlin et al., 1996) . In the presence of various amounts of SDF-1, GHOST-CCR5 or GHOST-CXCR4 cells were transduced at an m.o.i. of 0.5 with [MLV(SIVagm-wt)] or [MLV-(SIVagm-X4)] vectors, respectively. Two days after transduction, X-Gal staining revealed that the transduction efficiency of the [MLV(SIVagm-X4)] vector was reduced by SDF-1 in a dose-dependent manner down to 4.5% at an SDF-1 concentration of 4 g/ml, whereas the transduction efficiency of the [MLV(SIVagm-wt)] vector was not impaired (Fig. 6 ). These data demonstrate unequivocally the coreceptor switch of the [MLV(SIVagm)] pseudotype vector after V3-loop exchange.
[MLV(SIVagm-X4)] pseudotype vectors are resistant to neutralization by sera from HIV-1-infected individuals
In contrast to [MLV(HIV-X4)] vectors, [MLV(SIVagm-wt)] vectors have been shown to be relatively resistant to neutralization by anti-HIV-1 antibodies (Stitz et al., 2000) . By insertion of the HIV-1 V3-loop, this resistance to neutralization may have been decreased, as many of the neutralizing antibodies against HIV-1 have been shown to be directed against the V3-loop. Therefore, neutraliza- ] vectors, respectively, were incubated for 1 h at 37°C with sera and were then used for the transduction of the respective target GHOST cell line. The resulting titer was determined by X-Gal staining 2 days later (Fig. 7) . For comparison, the mean titer obtained after incubation with control sera from four healthy donors was set to 100%. Compared to these controls, the transduction titers of [MLV(HIV-X4)] vectors were reduced approximately 60% using the HIV-1-positive sera. In contrast, titers of [MLV(SIVagm-wt)] and [MLV(SIVagm-X4)] were approximately 6 to 19% reduced, which was in a similar range as observed for [MLV(MLV-A)] vector (22%). Thus, V3-loop substitution in [MLV-(SIVagm)] vector particles did not affect the absence from neutralization by sera from HIV-1 seropositives.
Transduction of primary human lymphocytes using [MLV(SIVagm-X4)] vectors
To test the ability of [MLV(SIVagm-X4)] vectors to transduce primary human peripheral blood lymphocytes (PBLs), vectors transferring the egfp gene were generated by transient triple transfection of 293T cells with MoMLV Gag/Pol expression plasmid pHIT60, the packaging vector plasmid pMgEGFP-⌬LNGFR, and the SIVagm-X4 env expression construct Rep⌬10env-X4.
[MLV(MLV-A)] vectors were generated similarly using MLV-A env expression construct ALF-MLV-A. PBL of three human donors were purified by Ficoll gradient centrifugation and stimulated for 3 days with immobilized monoclonal antibodies directed against CD3 and CD28 in the presence of IL-2. 5 ϫ 10 4 PBL were transduced on fibronectin-coated plates with 1 ml of supernatant from transiently transfected 293T. More than 95% of these cells expressed CD3 at the time of transduction, as assessed by anti-CD3 antibody labeling and FACS analysis (not shown). Three cycles of transduction were performed on consecutive days containing the total amount of 5 ϫ 10 4 i.u. of [MLV(SIVagm-X4)] or 1.5 ϫ 10 5 i.u. of [MLV(MLV-A)] vectors estimated on Molt4/8 cells. Three days after the last transduction, PBLs were analyzed by FACS for expression of EGFP and CD4 (Fig. 8, Table 1 ). Considering the low m.o.i. that had to be used due the low titer of the transiently generated egfp-transferring vectors, [MLV(SIVagm-X4)] vectors were thus shown to enable efficient gene transfer into the CD4-positive fraction of primary PBLs. Transduction levels varied between the three donors from 8.3 to 22.2%. As expected, CD4negative cells were not transduced, showing the receptor specificity of the modified vector. In contrast, the [MLV(MLV-A)] vector transduced both CD4-positive and CD4-negative cells with nearly equal efficiency for each donor.
Determining the coreceptor expression pattern of the transduced cultures revealed strong fluctuations in the numbers of CCR5-or CXCR4-expressing cells after transduction (data not shown). This was in accordance with a previous publication showing that, in contrast to CD4, the expression of CXCR4 and CCR5 in primary cells is not constitutive but strongly regulated and varies largely after stimulation, e.g., with IL-2 (Bleul et al., 1997) . It was therefore not possible to analyze the coreceptor usage of the vectors in primary cells. 
DISCUSSION
To generate retroviral vectors for the specific transduction of CD4-positive T cells in future gene therapy approaches of AIDS, MLV has been successfully pseudotyped with C-terminally truncated Env variants of HIV and SIV (Schnierle et al., 1997; Indraccolo et al., 1998; Lodge et al., 1998; Höhne et al., 1999; Stitz et al., 2000) . The env variants encoded a full-length SU and a C-terminally truncated TM. In contrast to [MLV(HIV-1)] vectors, [MLV(SIVagm)] vectors are resistant to neutralization by sera from HIV-1-seropositives and may therefore be suitable for in vivo gene therapy strategies in HIV-1-positive patients (Stitz et al., 1998) . However, only the small CCR5-or Bonzo-positive fraction of human CD4-positive T-lymphocytes can be transduced by [MLV-(SIVagm-wt)] vectors encoding the full-length SU of wt SIVagm3mc . Therefore, we intended to expand the tropism of [MLV(SIVagm-wt)] vectors to the majority of CD4-positive cells expressing CXCR4 by modifying the SIVagm SU.
In HIV-1, the V3-loop of SU was identified as the major determinant of CXCR4-and CCR5-coreceptor specificity (Hwang et al., 1991; Shioda et al., 1992; Choe et al., 1996; Speck et al., 1997) , whereas other Env sequences, in conjunction with V3, seem to be more important for SU binding to other coreceptors (Ross and Cullen, 1998; Hoffman et al., 1998) . In contrast, the determinants of the coreceptor tropism of SIV Env are not known in detail.
Major differences of V3-loops of SIV to those of HIV-1 have been reported. V3-loops of SIV isolates are highly conserved (Overbaugh et al., 1991; Owen et al., 2000) , and neutralizing antibodies directed against the respective V3-loops are only poorly induced (Javaherian et al., 1992 (Javaherian et al., , 1994 Glamann et al., 1998) . This may indicate a subtly different function of SIV compared to HIV-1 V3loops. Moreover, from a comparative sequence analysis of V3-loops of several SIV strains including SIVagm revealing a variety of different coreceptor usages, as well as from inconsistent inhibition experiments using various blocking compounds, it has been concluded that coreceptor usage of SIV isolates is also dependent on Env sequences other than the V3-loop (Owen et al., 2000) . A consensus motif that predicts coreceptor usage has been suggested up to now exclusively for HIV-1 strains but not for HIV-2 or SIV (Xiao et al., 1998; . On the other hand, there are some hints that V3-loops of SIV may play a similar role for coreceptor recognition as the respective V3-loop of HIV-1 (Kirchhoff et al., 1994b) . Monoclonal antibodies against the V3-loop of SIVmac blocked CCR5 binding (Edinger et al., 2000) , and exchange of single amino acids within the V3-loop influenced the usage of coreceptors other than CCR5 (Pohlmann et al., 1999) . We therefore hypothesized that the coreceptor usage of SIVagm may also be influenced by V3-loop exchange. With a view to future gene therapy applications we aimed at expanding the tropism of [MLV-(SIVagm)] vector particles. Thus, a 34 amino acid homolog of the HIV-1 V3-loop localized by sequence comparison in the SIVagm3mc SU was replaced by the 36 amino acid V3-loop of the CXCR4-tropic HIV-1 strain BH10. The SIVagm-X4 Env protein was shown to retain its fusion capacity and could be used to generate pseudotype vectors suitable for transduction of CD4/ CXCR4-positive target cells, proving incorporation of the Table 1. respective Env protein into infectious vector particles. However, the titer of the [MLV(SIVagm-X4)] vector was lower than that of the [MLV(SIVagm-wt)] vector. The reason for this is unknown. It may be caused by decreased particle production or by a given lower infectivity of the [MLV(SIVagm-X4)] particles, the latter due to a lower level of SIVagm-X4 Env proteins per particle or to a lower affinity of the SIVagm-X4 Env to the cellular receptors. As determined by Western blot analysis, the SIVagm-wt and SIVagm-X4-derived gp29-TM⌬10 proteins were present in comparable amounts in the supernatants of respective packaging cells. Thus, it can be concluded that expression or intracellular transport of the SIVagm-X4 Env protein was normal. Differences in the amount of the gp140-SU proteins detected by Western blot analysis are probably due to different extents of SU shedding.
Transduction studies of [MLV(SIVagm)] vectors on the GHOST cell panel including inhibition studies using SDF-1, the natural ligand of CXCR4, unequivocally proved a switch in coreceptor usage from CCR5/Bonzo to CXCR4 due to the V3-loop exchange. This shows that the SIVagm Env V3-loop is a major determinant of SIV coreceptor usage, although the amino acid homology between the sequences exchanged is only 33%. Until now, V3-loops have only been exchanged successfully between different strains of HIV-1 (Sato et al., 1999; La-Branche et al., 1999; I. Schmitt and K. Cichutek, unpublished data) or between HIV-1 and HIV-2 (Mamounas et al., 1995) . Efforts to switch coreceptor usage by V3-loop substitutions between SIVmac and HIV-1 have failed until now (Kirchhoff et al., 1994a; Meister et al., 2001; Mamounas et al., 1995) . Since in all cases the V3-loop regions were exchanged, it seems that the SIVagm Env proteins are more flexible than those of SIVmac.
The results described here demonstrate that a functional exchange of the V3-loop is possible between SIVagm and HIV-1. Moreover, the SIVagm SU was redirected toward CXCR4, although all but one (Schols and De Clercq, 1997) primary SIV strains isolated until recently revealed tropism for CCR5-positive cells and cannot use CXCR4 as a coreceptor (Chen et al., 1997; Kirchhoff et al., 1994b; Marx and Chen, 1998) . Recently, some SIV isolates have been described which can also use CXCR4 to a low extent in addition to their major coreceptor CCR5 (Owen et al., 2000) . Remarkably, the modified CXCR4-tropic SIVagm Env described here is no more able to use CCR5. Ongoing studies in our lab using replication-competent CXCR4-tropic SIVagm, modified by V3-loop exchange in an analogous way, will enlighten the significance of coreceptor usage for pathogenesis in monkeys (R. König and K. Cichutek, unpublished data).
Sera from HIV-1-positive donors are known to contain high levels of neutralizing antibodies against the V3-loop (Sattentau and Moore, 1995; Burton, 1997) . In contrast to [MLV(SIVagm-wt)], the [MLV(SIVagm-X4)] vector contains the V3-loop of an HIV-1 strain, which accordingly may enable neutralization by HIV-1-positive human sera. However, neutralization assays revealed a significantly lower neutralization activity against [MLV(SIVagm-X4)] vectors compared to [MLV(HIV-1)] when sera from four human HIV-1-positive donors were used. Since both vectors do possess the same V3-loop, the difference in neutralization sensitivity may be due to antigens presented in other Env regions than V3, or to different conformations of the same V3-loop in different contexts.
In summary, it was shown that by exchange of the V3-loop in SU of a CCR5/Bonzo-tropic [MLV(SIVagm)] vector by that of a CXCR4-tropic HIV-1 strain the coreceptor usage was changed accordingly. This result proves an essential function of V3 for coreceptor binding for simian lentiviruses as well as for HIV-1, either by direct binding or in conjunction with other Env regions. Since the new [MLV(SIVagm-X4)] vectors retained resistance against neutralization by HIV-1 sera and were able to transduce primary human CD4-positive lymphocytes, they may be useful tools for the delivery of therapeutic genes during the treatment of AIDS, in particular for in vivo applications. Although various protocols for transduction of T-lymphocytes ex vivo have been used in gene therapy, in vivo applications theoretically offer several advantages, e.g., the avoidance of a contamination risk or the risk of clonal selection during cultivation of lymphocytes ex vivo. However, although stable packaging cell lines were generated for the production of [MLV-(SIVagm-X4)] vectors, the titers of 6 ϫ 10 3 i.u./ml obtained here are too low to readily allow in vivo applications. Accordingly, further optimization of vector titers and large-scale production will be needed.
MATERIALS AND METHODS
Plasmids
MoMLV gag/pol expression construct pHIT60 (Soneoka et al., 1995) was obtained from A. Kingsman, Oxford, U.K. HIV-1 Env expression construct pTr712 (Wilk et al., 1992) , harboring a C-terminally truncated variant of the T cell tropic HIV-1 Env strain BH10 (Wong-Staal et al., 1985) , was a gift from V. Bosch (Heidelberg, Germany). pRep⌬10env codes for a C-terminally truncated form of SIVagm3mc env (Stitz et al., 2000) and also contains a hygromycin B selection cassette (Fig. 1A) . pMFG-nlsLacZ (Ferry et al., 1991) encoding a retroviral transfer vector derived from MLV encompassing the reporter gene lacZ was a gift of S. Russel, Cambridge, U.K. The retroviral transfer vector MgEGFP-⌬LNGFR codes for EGFP (Clontech, Palo Alto, CA) and a truncated low-affinity human nerve growth factor receptor (⌬LNGFR) which are expressed under the control of a murine stem cell virus (MSCV) LTR. Amphotropic MLV Env (MLV-A) expression construct pALF-MLV-A was generated according to Cosset et al. (1995) , by replacing the PERV Env of pFBMOALF (Takeuchi et al., 1998 ) by a PCR fragment containing the open reading frame of the amphotropic MLV env 4070A gene framed by XbaI-ClaI restriction sites.
Exchange of the V3-loop of SIVagm env by fusion PCR
pRep⌬10env-X4 was generated by precise replacement of the V3-loop of SIVagm in pRep⌬10env by the V3-loop of HIV-1 strain BH10 using standard PCR and fusion-PCR techniques as described in Fig. 2 . Primer sequences are available upon request. Amino acid sequences of the V3-loops of HIV-1 strains BH10 (Wong-Staal et al., 1985) and MBK (Cichutek et al., 1992) and of wild-type SIVagm3mc are shown in Fig. 1B .
Cell lines
The human kidney cell line 293T (gift of M. Grez, Georg-Speyer-Haus, Frankfurt, Germany), the human rhabdomyosarcoma cell line TE671 (Stratton et al., 1989) , and the env-negative TE671-derived MLV packaging cell line TELCeB6 (kindly provided by Y. Takeuchi and F.-L. Cosset, Chester Beatty Laboratories, London, U.K.) (Cosset et al., 1995) as well as the TELCeB6-derived clone K52SR20 (Stitz et al., 1998) , were grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO/BRL, Eggenstein, Germany) supplemented with 10% heat-inactivated FCS (Seromed, Biochrom KG, Berlin, Germany), 1% streptomycin/penicillin, and 2 mM L-glutamine. All TELCeB6derived packaging cell clones were permanently cultured in the presence of 5 g/ml blasticidine S (ICN) and 4.5 g/l glucose. The human osteosarcoma cell line (HOS)-derived GHOST cell panel (provided by M. Dittmar, Heinrich-Pette-Institut, Hamburg, Germany) expressing one of various coreceptors in addition to human CD4 and a tat-dependent GFP were cultivated as described (Cecilia et al., 1998) . The human T cell line Molt4/8 was maintained in RPMI 1640 medium containing 10% FCS, 1% streptomycin/penicillin, and 2 mM L-glutamine.
Transient vector production 6 ϫ 10 5 293T cells were seeded the day before transfection in six-well culture plates (Nunc). Cells were transfected with 1 g plasmid DNA of each expression construct (pHIT60, pMFG-nlsLacZ, or pMgEGFP-⌬LNGFR and one of the Env variant encoding constructs) using LipofectAMINE Plus according to manufacturer's instructions (GIBCO/Life Technologies). One day after transfection, the medium was replaced by fresh medium. To increase vector production, 10 mM sodium butyrate (NaB) was added (Olsen and Sechelski, 1995) . Vectorcontaining supernatant was harvested 6 to 14 h after medium exchange.
Generation of stable vector producer cell lines
To establish packaging cell lines continuously producing [MLV(SIVagm-wt)] and [MLV(SIVagm-X4)] vector par-ticles, 5 ϫ 10 5 TELCeB6 cells were transfected with 3 g of plasmids pRep⌬10env or pRep⌬10env-X4, both coding for a hygromycin B resistance gene in addition to the SIVagm Env variant. Following hygromycin B selection (200 g/ml; Boehringer Mannheim, Mannheim, Germany), resistant cell colonies were tested for production of vector particles able to transduce the respective GHOST target cell line. Titrations with serial dilutions of vector-containing supernatant were performed on GHOST-CCR5 or GHOST-CXCR4 cells as described elsewhere (Schnierle et al., 1997) .
Similarly, the packaging cell line MBK15 which produces CCR5-tropic vector particles [MLV(HIV-R5)] was established by transfection of TELCeB6 cells with the CCR5-tropic HIV-1-env construct pTr712MBK and subsequent G418 selection (800 g/ml) and screening for vector production (I. Schmitt and K. Cichutek, unpublished data).
Furthermore, a stable producer cell line for [MLV(MLV-A)] vectors was generated by transfecting TELCeB6 cells with the amphotropic MLV (4070A) Env encoding construct pALF-MLV-A, harboring the resistance gene for phleomycin. Bulk packaging cells were established by selection in the presence of 50 g/ml phleomycin (CAYLA, Toulouse, France). Vector titer was determined on the GHOST-parental cell line as described elsewhere (Schnierle et al., 1997) .
Membrane fusion and in situ immunoperoxidase assay
293T cells were transfected with plasmids encoding the SIVagm env variants. On the following day, transfected cells were overlaid with Molt4/8 T cells and cocultivated for 2 days. Env-positive cells were detected by in situ immunoperoxidase staining. Therefore, cells were fixed by incubation with ice-cold methanol for 15 min. After repeated washing with PBS, blocking buffer (2% BSA in PBS) was added for 1 h at room temperature. Cells were washed again and incubated at room temperature with serum from an SIVagm3-infected pig-tailed macaque (Macaca nemestrina) designated Nem170 in a 1:400 dilution. After further washing, cells were incubated with peroxidase-conjugated protein-G (Bio-Rad, Krefeld, Germany). Finally, antigen-expressing cells were visualized by addition of substrate buffer (H 2 O 2 /3-amino-9-ethylcarbazol, Sigma, Deisenhofen, Germany).
Vector harvest and determination of titers
Ninety percent confluent cultures of packaging cells were incubated with little volume of cell culture medium (10 ml per 182 cm 2 flask) for 6 to 14 h. Supernatants were filtrated (0.45 m), in some cases concentrated by ultracentrifugation (35,000 rpm in a Beckman SW41 rotor for 1.5 h at 4°C), resuspended in PBS, and stored at Ϫ80°C until use.
GHOST target cells were seeded in 12-well (1 ϫ 10 5 cells per well) or 24-well (4 ϫ 10 4 cells per well) culture dishes. Five hundred microliters of serial dilutions of vector-containing supernatants were added, incubated for 3 h, and washed off. Two days posttransduction, cells were analyzed for ␤-Gal activity (Sanes et al., 1986) . Vector titers were calculated as described elsewhere (Schnierle et al., 1997) and given as infectious units per milliliters.
Inhibition of transduction in the presence of SDF-1
One day before transduction. 2 ϫ 10 4 GHOST-CCR5 and GHOST-CXCR4 cells were seeded in 48-well culture plates (Nunc). The cells were incubated with various concentrations of SDF-1␣ (0.25-4 g/ml; R&D Systems, Wiesbaden, Germany) 2 h prior to transduction. Added to the SDF-1-containing media were 1 ϫ 10 4 i.u. of [MLV-(SIVagm-wt)] or [MLV(SIVagm-X4)] vector particles, respectively. After a 3 h incubation period, the supernatants were removed and the cells were further cultivated in the presence of SDF-1. Two days posttransduction, cells were analyzed for ␤-Gal activity (Sanes et al., 1986) .
Western blot analysis of vector particles
Viral particles were pelleted from packaging cell supernatants by ultracentrifugation through 20% sucrose cushions in PBS at 35,000 rpm in a Beckman SW41 rotor for 1.5 h at 4°C. Pellets were resuspended in PBS, subjected to 10% SDS-PAGE, and transferred to a polyvinylide fluoride (PVDF) membrane (Millipore, Eschborn, Germany). Staining was performed using serum from an SIVagm3-infected pig-tailed macaque (M. nemestrina) designated Nem170, diluted 1:1000, and horseradish peroxidase coupled protein G at a dilution of 1:1000, using the enhanced chemiluminescence Western blot detection kit (Amersham Pharmacia Biotech, Freiburg, Germany). Detection of MLV gag proteins was performed using a polyclonal anti-RLVp30gag serum in a 1:10,000 dilution (Viromed, NJ).
Neutralization assays
Sensitivity to neutralization by sera from HIV-1-infected donors was tested by incubating 5 ϫ 10 3 i.u. of vector particles with 1:20 dilution of heat-inactivated sera from HIV-1-infected donors or uninfected controls in a total volume of 200 l for 1 h at 37°C. Samples were then used to transduce 2 ϫ 10 4 GHOST-CXCR4 cells in 48well dishes as described. Vector titers were estimated after X-Gal staining of transduced cells.
Isolation and transduction of primary T-lymphocytes
Peripheral blood mononuclear cells (PBMC) were obtained from healthy donors and isolated by centrifugation on Ficoll-Histopaque (Sigma) and subsequent erythro-cyte lysis in a 0.86% NH 4 Cl solution. Cells were adjusted to a concentration of 1 ϫ 10 6 cells per ml and stimulated for 72 h with immobilized monoclonal antibodies, anti-CD3, and anti-CD28 (Becton-Dickinson) in X-Vivo 10 medium (BioWhittaker, Walkersville, MD) supplemented with antibiotics, glutamine, 100 U/ml IL-2 (Chiron), 10% FCS, and 10% autologous plasma. Autologous plasma was obtained during purification of the PBMC and inactivated for 1 h at 56°C before use.
After 3 days of stimulation, 24-well nontissue culture plates (BD Falcon) precoated with the recombinant fibronectin fragment RetroNectin (TaKaRa Biomedicals, Otsu, Japan) (Fehse et al., 1998) , 5 ϫ 10 4 PBL suspended in 250 l fresh medium, and 1 ml vector supernatant from transiently transfected 293T was added, and the medium was adjusted to a final concentration of 1 g/ml protamine sulfate and 100 U/ml IL-2. The cell culture plates were centrifuged for 90 min at 1000 rpm, 32°C in a Varifuge 3.OR (Heraeus) centrifuge, and subsequently incubated for 3 h at 37°C (Costello et al., 2000) . Half of the medium was exchanged by fresh medium. Three cycles of transduction were performed on consecutive days. Subsequently, the cells were kept for 3 days in medium containing 100 U/ml IL-2.
Determination of gene transfer into PBL by FACS analysis
Transduction efficiencies were assessed by flow cytometry measuring EGFP and CD4 expression. Three days after the last transduction, 2 ϫ 10 5 PBL were washed and resuspended in 30 l of 2% BSA, 0.01% NaN 3 in PBS and stained for 30 min with 5 l of anti-CD4 antibody (PerCP-conjugated, Becton-Dickinson) at 4°C. Cells were washed twice with 500 l of 2% BSA, 0.01% NaN 3 in PBS. After fixation in 1% paraformaldehyde, the cells were analyzed on a Galaxy flow cytometer (DAKO, Copenhagen, Denmark).
